Erkang Pharmaceutical (300267.SZ) announced first-half results, with net profit of 444.69 million yuan to mother, an increase of 18.16% over the previous year

According to the Zhitong Finance App, Erkang Pharmaceutical (300267.SZ) released its 2026 semi-annual report. During the reporting period, the company achieved revenue of 568 million yuan, a year-on-year decrease of 16.77%. Net profit attributable to shareholders of listed companies was 444.69 million yuan, an increase of 18.16% over the previous year. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 41.897 million yuan, an increase of 24.75% over the previous year.

During the reporting period, the company's main businesses of new energy+pharmaceuticals made efforts in both directions. By deepening refined production management and technical upgrading, NEV's lithium ore processing plant in Nigeria has improved the recycling rate and product quality. Combined with the sharp rise in product market prices over the same period and the application of hedging tools, it has effectively guaranteed the stable contribution of the NEV materials business. The traditional excipients business focuses on the import substitution window, and core injectable excipients are deeply tied to innovative drug customers through customized services to achieve steady revenue growth. The modified starch and vegetable capsule sector keeps an eye on global plant-based consumption trends, and relies on integrated solutions to drive rapid growth in overseas market penetration rates. At the same time, the improvement of the API matrix has strengthened the synergy effect of “integration of raw materials and excipients”, while the digital layout of “AI+ excipients” is poised for medium- to long-term growth. Overall, the company became the main factor driving its performance in the first half of the year through production efficiency improvement, product structure optimization and market expansion.